KromaTiD key facts
as of Oct 2026- Developer of next-gen cytogenetic products focused on discovering, detecting, and diagnosing genomic rearrangements in the areas of oncology and rare diseases.
- KromaTiD is valued at approximately $39.0M as of Oct 2026, set at its later-stage round, Jul 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $23.6M across 5 recorded rounds; the latest was Seed Round ($3.6M) in Jul 2025.
- Notable investors include National Institutes of Health, Innosphere Ventures, Colorado Office of Economic Development & International Trade, BroadOak Capital Partners, CSU Starta — 11 tracked in total.
- KromaTiD has filed 8 Form Ds with the SEC since 2013, most recently Jul 2025 ($3.6M sold to 57 investors).
- Status: Privately Held (backing).
Valued at $39.0M at its later-stage round, Jul 2025. Nothing has traded since.
- ·The complete investor list: 11 names
- ·Watch KromaTiD: the Monday email on marks, rounds and moves
KromaTiD funding rounds
5 roundsWho backs KromaTiD
11+Membership and data by Private Market View
KromaTiD valuation
KromaTiD was valued at $39 million at its later-stage round in Jul 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has KromaTiD raised?
KromaTiD has raised $23.6 million across 5 recorded rounds since 2016. The largest was a $7.9 million early-stage round in Sep 2021; the most recent was a $3.6 million seed round in Jul 2025.
KromaTiD has filed 8 Form Ds with the SEC since 2013, most recently in Jul 2025 ($3.6 million sold to 57 investors).
KromaTiD investors
11 investors are on record for KromaTiD, including National Institutes of Health, Innosphere Ventures, Colorado Office of Economic Development & International Trade and BroadOak Capital Partners. The seed round in Jul 2025 drew 57 investors.
About KromaTiD
Developer of next-gen cytogenetic products focused on discovering, detecting, and diagnosing genomic rearrangements in the areas of oncology and rare diseases. The company's molecular cytogenetic and genetracker tests discover, detect, and diagnose the widest range of disease-causing mutations, including inversions and translocations, in a single test, enabling research teams in academia, pharma, and biopharma to accelerate the delivery of novel therapeutics to the patients who need them.
- Sector
- Healthcare
- HQ
- Longmont, CO, United States
- Founded
- 2007
- Employees
- 35
- Website
- kromatid.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.